NOVANTA INC — Form 8-K/A
Filed October 2, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 42/100
What the filing says
On July 23, 2026, Novanta Inc. completed acquisition of Runway Buyer, LLC (Riverpoint Medical) for approximately $1.2 billion cash plus $250 million milestone payment due by January 8, 2027. Runway Buyer generated $136.1M revenue and $11.5M net income in 2025; $33.5M revenue and $2.4M net income in Q1 2026. Transaction funded via $616M debt borrowings and $287.6M equity issuance (2.1M shares at ~$134/share). Runway Buyer's $206.1M term debt was repaid at closing.
Why this rating
Deal value ~41% of Novanta's $3.5B market cap—material but manageable. Riverpoint adds $136M annual revenue (~14% of Novanta's $981M 2025), yet low margins (8.4% net) dilute pro forma EPS. Debt financing modest relative to company size. Significance moderate: meaningful acquisition but not transformational; dilutive earnings accretion offset by strategic diversification into surgical devices.
See more from October 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.